Search results for retatrutide
Industry
Retatrutide shows knee osteoarthritis pain relief in trials
Eli Lilly’s next-generation obesity treatment retatrutide showed effectiveness in weight loss and easing knee osteoarthritis pain in large clinical trials. In two phase 3 studies published in The New England Journal of Medicine, weekly injections produced greater weight reduction and improved pain scores than placebo in overweight or obese adults without type 2 diabetes who also had knee osteoarthritis. Serious adverse events were more frequent than with placebo, with common side effects including nausea and diarrhoea.
Industry
Lilly\'s next-generation obesity drug retatrutide shows 25 percent weight loss in 80 weeks
Eli Lilly\'s next-generation obesity drug candidate retatrutide showed an average 25 percent weight loss at the highest dose after 80 weeks in a Phase 3 trial. Among participants who extended treatment to 104 weeks, average weight loss rose to 30 percent. Results were published in the New England Journal of Medicine, with more than one-third losing at least 30 percent of body weight. The study did not directly compare retatrutide with existing obesity drugs, and researchers said further trials are needed.
Industry
Lily\'s new obesity drug retatrutide eyes beyond GLP-1 limits tagged with fatigue
Eli Lilly\'s next-generation obesity treatment retatrutide may reduce fatigue, a side effect often associated with GLP-1 drugs, by regulating energy metabolism as well as suppressing appetite. Retatrutide is designed as a triple agonist that stimulates GLP-1, GIP and glucagon receptors. This mechanism could promote fat and glycogen breakdown while boosting insulin and limiting blood sugar spikes. Gigazine said clinical data are not yet sufficient to confirm the effect.